Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:EVAX NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$3.70-10.0%$4.93$3.32▼$19.80$21.52M2.0551,521 shs63,805 shsEVAXEvaxion A/S$9.60-12.8%$3.94$1.20▼$15.50$15.44M0.234.64 million shs891,075 shsPMVPPMV Pharmaceuticals$1.44$1.41$0.81▼$1.84$76.31M1.51649,349 shs592,256 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-0.72%-6.59%+4.05%-54.47%-75.32%EVAXEvaxion A/S+40.43%+75.04%+277.05%+315.47%-18.14%PMVPPMV Pharmaceuticals+1.41%+1.41%+26.32%+8.27%-3.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$3.70-10.0%$4.93$3.32▼$19.80$21.52M2.0551,521 shs63,805 shsEVAXEvaxion A/S$9.60-12.8%$3.94$1.20▼$15.50$15.44M0.234.64 million shs891,075 shsPMVPPMV Pharmaceuticals$1.44$1.41$0.81▼$1.84$76.31M1.51649,349 shs592,256 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical-0.72%-6.59%+4.05%-54.47%-75.32%EVAXEvaxion A/S+40.43%+75.04%+277.05%+315.47%-18.14%PMVPPMV Pharmaceuticals+1.41%+1.41%+26.32%+8.27%-3.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 2.17Hold$63.001,602.70% UpsideEVAXEvaxion A/S 2.33Hold$11.0014.58% UpsidePMVPPMV Pharmaceuticals 2.33Hold$5.50281.94% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, PMVP, and CLSD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025EVAXEvaxion A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EVAXEvaxion A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PMVPPMV PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025EVAXEvaxion A/SHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.007/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$75.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$30.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$45.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$1.66M11.68N/AN/A($7.68) per share-0.48EVAXEvaxion A/S$3.34M4.02N/AN/A($1.18) per share-8.14PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$5.55N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)EVAXEvaxion A/S-$10.57M-$1.32N/AN/AN/AN/A-319.52%-63.56%10/30/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.57N/AN/AN/AN/A-47.94%-43.82%11/6/2025 (Estimated)Latest EVAX, PMVP, and CLSD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CLSDClearside Biomedical-$0.67N/AN/AN/A$0.09 millionN/A11/6/2025Q3 2025PMVPPMV Pharmaceuticals-$0.40N/AN/AN/AN/AN/A8/14/2025Q2 2025EVAXEvaxion A/S-$0.50-$0.76-$0.26-$0.76N/A$0.04 million8/8/2025Q2 2025CLSDClearside Biomedical-$1.80-$0.90+$0.90-$0.06$0.50 million$0.49 million8/7/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39-$0.41-$0.02-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87EVAXEvaxion A/S1.733.423.42PMVPPMV PharmaceuticalsN/A12.5212.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%EVAXEvaxion A/S11.04%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%EVAXEvaxion A/S41.64%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical305.24 million4.89 millionOptionableEVAXEvaxion A/S601.40 million819,000No DataPMVPPMV Pharmaceuticals5052.99 million48.98 millionOptionableEVAX, PMVP, and CLSD HeadlinesRecent News About These CompaniesWeiss Ratings Reiterates "Sell (D-)" Rating for PMV Pharmaceuticals (NASDAQ:PMVP)October 14 at 2:42 PM | marketbeat.comPMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular ...October 13 at 8:07 PM | finance.yahoo.comPMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 13 at 4:01 PM | globenewswire.comFY2026 Earnings Estimate for PMVP Issued By HC WainwrightSeptember 22, 2025 | marketbeat.comPMV Pharmaceuticals (NASDAQ:PMVP) Major Shareholder Sells $900,000.00 in StockSeptember 13, 2025 | insidertrades.comPMV Pharmaceuticals stock soars after promising cancer drug trial resultsSeptember 10, 2025 | za.investing.comPMV Pharmaceuticals Shares Jump After Positive Cancer Drug Trial DataSeptember 10, 2025 | msn.comPMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationSeptember 10, 2025 | globenewswire.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 7, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 7, 2025 | globenewswire.comRobert Ticktin Sells 23,151 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) StockJuly 4, 2025 | insidertrades.comPmv Pharmaceuticals Inc (PMVP) - Investing.comJuly 3, 2025 | investing.comPMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare AdvancesMay 23, 2025 | quiverquant.comQPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comWe're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn RateMay 18, 2025 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finanznachrichten.dePMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 9, 2025 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%April 21, 2025 | aaii.comAHere's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom FishingMarch 5, 2025 | zacks.comPMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)March 3, 2025 | markets.businessinsider.comPMV Pharmaceuticals sees cash runway to end of 2026March 3, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, PMVP, and CLSD Company DescriptionsClearside Biomedical NASDAQ:CLSD$3.70 -0.41 (-9.98%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.04 (+1.08%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Evaxion A/S NASDAQ:EVAX$9.60 -1.41 (-12.81%) Closing price 04:00 PM EasternExtended Trading$9.27 -0.33 (-3.44%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.PMV Pharmaceuticals NASDAQ:PMVP$1.44 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
